Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Pancreatic Neoplasms: HELP
Articles by Teresa Gagliano
Based on 1 article published since 2009
(Why 1 article?)
||||

Between 2009 and 2019, Teresa Gagliano wrote the following article about Pancreatic Neoplasms.
 
+ Citations + Abstracts
1 Article Targeting protein kinase C by Enzastaurin restrains proliferation and secretion in human pancreatic endocrine tumors. 2011

Molè, Daniela / Gagliano, Teresa / Gentilin, Erica / Tagliati, Federico / Pasquali, Claudio / Ambrosio, Maria Rosaria / Pansini, Giancarlo / Degli Uberti, Ettore C / Zatelli, Maria Chiara. ·Section of Endocrinology, Department of Biomedical Sciences and Advanced Therapies, University of Ferrara, Italy. ·Endocr Relat Cancer · Pubmed #21606156.

ABSTRACT: Dysregulation of the protein kinase C (PKC) signaling pathway has been implicated in tumor progression. In this study, we investigate the effects of a PKC inhibitor, Enzastaurin, in human pancreatic neuroendocrine neoplasms (PNN) primary cultures and in the human pancreatic endocrine cancer cell line, BON1. To this aim six human PNN dispersed in primary cultures and BON1 cells were treated without or with 1-10 μM Enzastaurin and/or 100 nM IGF1 in the presence or absence of serum. Cell viability and apoptosis were evaluated after 48-72 h; Chromogranin A (CgA) and/or insulin secretion was assessed after 6 h of incubation. PKC expression was investigated by immunofluorescence and western blot. We found that Enzastaurin significantly reduced human PNN primary culture cell viability, as well as CgA and insulin secretion. Moreover, in the BON1 cell line Enzastaurin inhibited cell proliferation at 5 and 10 μM by inducing caspase-mediated apoptosis, and reduced phosphorylation of glycogen synthetase kinase 3β (GSK3β) and of Akt, both downstream targets of PKC pathway and pharmacodynamic markers for Enzastaurin. In addition, Enzastaurin blocked the stimulatory effect of IGF1 on cell proliferation, and reduced CgA expression and secretion in BON1 cells. Two different PKC isoforms are expressed at different levels and have partially different subcellular localization in BON1 cells. In conclusion, Enzastaurin reduces cell proliferation by inducing apoptosis, with a mechanism likely involving GSK3β signaling, and inhibits secretory activity in PNN in vitro models, suggesting that Enzastaurin might represent a possible medical treatment of human PNN.